Medtronic completes CathWorks acquisition

Medtronic has completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease assessment. The acquisition is valued at $585M, with potential undisclosed earn-out payments after closing.

The deal adds the CathWorks FFRangio system to Medtronic’s interventional cardiology portfolio. The system is commercially available in the U.S., Europe, and Japan, according to Medtronic.

FFRangio uses AI and computational science to provide physiological assessment of the coronary tree from routine coronary angiograms. Medtronic said the system does not require drug stimulation or invasive pressure wires.

The platform differs from traditional wire-based fractional flow reserve assessment, which uses pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location in the vessel, according to the company.

Medtronic said the system delivers FFR values across the coronary tree. The company also said it provides information to help physicians select device size for treatment and calculate the effect of lesion treatment.

The acquisition follows a 2022 strategic partnership and co-promotion agreement between the companies.

Medtronic said the transaction is expected to be immaterial to fiscal year 2027 GAAP and adjusted earnings per share and neutral to accretive afterward.